1[1]Lu ZH,Robert BD.Dihydropyrimidine Dehydrogenase Activity and Fluorouracil Chemotherapy.Journal of Clinical Oncology,Edtorial,1994,Vol12(11):2239-2242.
2[2]Lu ZH,Zhang RW,and Robert BD.Dihydropyrimidine Dehydrogenase Activity in Human Peripheral Blood Mononuclear Cells and Liver:Population Characteristics,Newly Identified Deficient Patients,and Clinical Implication in 5-Fluorouracil Chemotherapy.Cancer Research,1993,53(11):5433-5438.
3[3]Guimbaud R,Guichard S,Dusseau C,et al.Dihydropyrimidine dehydrogenase activity in normal,inflammatory and tumor tissues of colon and liver in humans.Cancer Chemother Pharmacol,2000,45(6):477-482.
4[4]Mcleod HL,Sluden J,Murray GI,et al.Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors.British Journal of Cancer,1998,77(3):461-465.
5[5]Barry EH,Song R,Soong S J,et al.Ralationship between Dihydropyrimidine Dehydrogenase Activity and Plasma 5-Fluorouracil Levels with Evidence for Circadian Variation of Enzyme Activity and Plasma Drug Levels in Cancer Patients Receiving 5-Fluorouracial by Protracted Continuous Infusion.Cancer Research ,1990,50(1):197-201.
7[7]Gamelin E,Boisdron-Celle M,Guerin-Meyer V,et al.Correlation between Uracil and Dihydrouracil Plasma Ratio,Fluorouracil(5-Fu)Pharmacokinetic Parameters,and Tolerance in Patients with Advanced colorectal Cancer :A Potential Interest for Predicting 5-Fu Toxicity and Determining Optimal 5-Fu Dosage.Journal of Clinical Oncology,1999,Vol 17(4):1105-1110.
8[8]Etienne MC,Lagrange JL,Dassonville O,et al.Population Study of Dihydropyrimidine Dehydrogenase in Cancer Patients.Journal of Clinical Oncology,1994,Vol12(11):2248 2253.
9[9]Takenoue T,Kitayama J,Takei Y,et al.Characterization of dihydropyrimidine dehydrogenase on immunohis tochemical in colon carcinoma,and correlation between immunohistochemical score and protein level or messen ger RNA expression.Annals of Oncology,2000,11(3):273-279.
10[10]Uetake H,Ichikawa W,Takechi T,et al.Relationship between Intratumoral Dihydropyrimidine Dehydrogenase Activity and Gene Expression in Human Colorectal Cancer.Clinical Caner Research,1999,Vol5(10):2836-2839.
同被引文献13
1[1]Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil [J]. Clin Cancer Res,1999,5(8): 2006-2011.
2[2]van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD)deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene [J].Clin Cancer Res, 2000, 6(12): 4705 -4712.
3[3]Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU) -related toxicity compared with controls [J]. Clin Cancer Res, 2001, 7(9):2832 - 2839.
4[4]van Kuilenburg AB. Dihydropyrimidine dehydrogenase and efficacy and toxicity of 5-fluorouracil [J]. Eur J Cancer, 2004,40(7): 939 - 950.
5[6]Guimbaud R, Guichard S, Dusseau C, et al. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumor tissues of colon and liver in humans [J]. Cancer Chemother Pharmacol,2000, 45(6): 477-482.
6[7]Mcleod HL, Sludden J, Murray GI, et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors [J]. BrJ Cancer, 1998, 77(3): 461-465.
7[8]Kobayashi K, Sumi S, Kidouchi K, et al. A case of gastric cancer with decreased dehydropyrimindine dehydrogenase activity [J]. Gan To Kagaku Ryoho, 1998, 25(8): 1217 - 1219.
8[9]Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al.Correlation between Uracil and Dihydrouracil Plasma Ratio,Fluorouracil(5-FU) Pharmacokinetic Parameters, and Tolerance in Patients with Advanced colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage [J]. J Clin Oncol, 1999, 17 (4): 1105-1110.
9[12]Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion [J].Cancer Res, 1990, 50(1): 197-201.
10[13]Lu Z, Zhang R, Robert RB. Dihydropyrimidine Dehydrogenase Activity in Human Peripheralthe blood Mononuclear Cells and Liver: Population Characteristics, Newly Identified Deficient Patients, and Clinical Implication in 5-Fluorouracil Chemotherapy [J]. Cancer Res, 1993, 53 (22): 5433-5438.
